Welcome to our dedicated page for InMode Ltd. Ordinary Shares news (Ticker: INMD), a resource for investors and traders seeking the latest updates and insights on InMode Ltd. Ordinary Shares stock.
InMode Ltd. (NASDAQ: INMD) is a leading global provider of innovative medical technologies specializing in minimally and non-invasive surgical aesthetic and medical treatment solutions. The company's product portfolio spans three major energy-based treatment categories: face & body contouring, medical aesthetics, and women's health. Their products, such as BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, are widely utilized in plastic surgery, dermatology, gynecology, and ophthalmology.
InMode’s flagship products, including Fractora for skin texture improvement, Lumecca for photorejuvenation, Diolaze for hair removal, and BodyFX for body contouring, are designed to deliver effective and exciting aesthetic solutions.
InMode has consistently invested in research and development to expand its intellectual property portfolio, which is pivotal for maintaining its competitive edge. Recently, the company initiated legal action against BTL Industries for patent infringement regarding their radio-frequency based feminine rejuvenation products.
Despite market headwinds, including higher interest rates affecting equipment financing and slower purchase decisions, InMode has shown resilience with a 2% increase in Q3 2023 revenues, totaling $123.1 million. The company also saw a 13% rise in international sales during this period.
In Q1 2024, InMode announced pre-orders for two new platforms, IgniteRF and Optimus Max, which are anticipated to drive future growth. Additionally, a new share repurchase program and the appointment of Dr. Michael Anghel as Chairman of the Board underscore the company’s commitment to shareholder value.
InMode's innovative spirit is further highlighted by their recent partnership with P1 Offshore Racing, sponsoring the only female driver, Victoria Rand, signaling a strong commitment to empowering women.
For more detailed information and the latest updates, visit InMode's official website.
InMode Ltd. (Nasdaq: INMD) has launched the EmpowerRF Women's Wellness technology in Canada after receiving certification from Health Canada. This advancement aims to improve urinary incontinence symptoms (SUI) and builds upon existing licenses for Genitourinary Syndrome of Menopause (GSM) and chronic pelvic pain. The EmpowerRF platform offers advanced therapies, including intravaginal electrical muscle stimulation and bipolar radiofrequency. InMode emphasizes its commitment to enhancing women's health through effective, minimally invasive solutions. This initiative reflects a strategic milestone for InMode in the global healthcare market.
InMode Ltd. (Nasdaq: INMD), a prominent global provider of innovative medical technologies, announced participation in the UBS Healthcare One-on-One Virtual Day on June 1, 2022. CEO Moshe Mizrahy and CFO Yair Malca will represent the company. Interested parties can schedule meetings through their UBS representative or by contacting Miri Segal at msegal@ms-ir.com. InMode specializes in medical devices using radiofrequency technology, serving various medical fields including plastic surgery and dermatology.
InMode Ltd. (NASDAQ: INMD) reported Q1 2022 revenues of $85.9 million, a 31% year-over-year increase. GAAP net income was $31 million, reflecting a 16% rise from the prior year, achieving GAAP diluted EPS of $0.36. The company noted record consumable revenues of $14 million, up 79% year-over-year. Despite facing global supply chain challenges affecting gross margins, management reiterated a full-year revenue guidance of $415-$425 million and robust long-term gross margin targets of 84%-86%.
InMode Ltd (Nasdaq: INMD) announced its expected financial results for Q1 2022, projecting revenue between $85.0 million and $85.5 million and non-GAAP earnings per diluted share between $0.38 and $0.39. The company noted an 83% to 84% gross margin, reflecting growth in demand for its minimally invasive solutions. Despite challenges from COVID-19 variants and supply chain issues, InMode managed to maintain productivity and meet delivery expectations. A conference call is scheduled for May 2, 2022, to discuss the results further.
InMode Ltd. (Nasdaq: INMD), a leading provider of innovative medical technologies, will participate in a virtual fireside chat at the 21st Annual Needham Healthcare Conference on April 14, 2022, at 4:30 p.m. ET. The event will feature CEO Moshe Mizrahy, CFO Yair Malca, and CMO Dr. Spero Theodorou, hosted by CFA Mike Matson. Management will also hold one-on-one meetings that day. A live link for the chat is available here, with more info on InMode's investor relations site.
InMode Ltd. (Nasdaq: INMD) announced a new share repurchase program, approving the buyback of up to 1 million ordinary shares. This decision follows the successful completion of a previous buyback in September 2020, reflecting the company's confidence in its long-term outlook. The program, funded by available cash, aims to enhance shareholder value and follows a trend of fiscally responsible investments. The board emphasized strong cash flow and a robust balance sheet as key factors justifying the buyback.
InMode Ltd. (Nasdaq: INMD) announced participation in two investor conferences in March 2022. The company will host a virtual fireside chat at the Oppenheimer 32nd Annual Healthcare Conference on March 15, at 10:40 a.m. EST. Additionally, InMode will present in-person at the Barclays Global Healthcare Conference on March 17, at 9:00 a.m. EST, located at the Loews Miami Beach Hotel. These events provide opportunities for one-on-one meetings with investors. For further details, visit InMode's website.
InMode Ltd. (Nasdaq: INMD) reported strong financial results for Q4 and FY 2021, with quarterly revenues reaching a record $110.5 million, a 47% increase year-over-year. The company achieved a GAAP net income of $52.7 million for Q4, and $165 million for the full year, compared to $75 million in 2020. Full year revenues totaled $357.6 million, a 73% increase. The company expects revenues for 2022 in the range of $415-$425 million with non-GAAP earnings per diluted share between $2.06 and $2.11. InMode continues to expand internationally and maintain healthy gross margins of 85%.
InMode Ltd. (Nasdaq: INMD) announced its anticipated financial results for the fourth quarter and full year 2021, revealing record revenues. The company expects fourth quarter revenue between $109.5M and $110M, and full year revenue of $356.5M to $357M, surpassing earlier guidance of $343M to $347M. Non-GAAP earnings per diluted share are forecasted at $0.61 for Q4 and $2.02 to $2.03 for the full year. Looking ahead, InMode projects 2022 revenues between $415M and $425M.
InMode Ltd. (Nasdaq: INMD), a global leader in innovative medical technologies, will present at the 24th Annual Needham Virtual Growth Conference on January 12, 2022, at 9:15 am EST. CEO Moshe Mizrahy and CFO Yair Malca will lead the presentation, which will be webcast live and archived for 90 days. Management will also offer one-on-one virtual meetings during the event. InMode specializes in minimally invasive radio-frequency technologies for various medical fields, including plastic surgery and dermatology.
FAQ
What is the current stock price of InMode Ltd. Ordinary Shares (INMD)?
What is the market cap of InMode Ltd. Ordinary Shares (INMD)?
What products does InMode Ltd. offer?
What are InMode's core business categories?
Which markets does InMode serve?
How did InMode perform in Q3 2023?
What are some of InMode's flagship products?
What recent legal actions has InMode taken?
What new platforms has InMode recently announced?
Who is the new Chairman of InMode's Board?
What partnership has InMode recently entered into?
Where can I find more information about InMode?
